PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
178.96%
R&D growth above 1.5x CRVO's 5.59%. Michael Burry would check for spending discipline.
203.49%
G&A growth above 1.5x CRVO's 37.03%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
-29.56%
Other expenses reduction while CRVO shows 100.00% growth. Joel Greenblatt would examine efficiency.
185.87%
Operating expenses growth 50-75% of CRVO's 251.41%. Bruce Berkowitz would examine efficiency.
185.87%
Total costs growth above 1.5x CRVO's 15.98%. Michael Burry would check for inefficiency.
-0.66%
Interest expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
-29.56%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-185.91%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-185.87%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
15.24%
Other expenses growth while CRVO reduces costs. John Neff would investigate differences.
-92.79%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-0.66%
Tax expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
-92.79%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-3998.91%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-3998.91%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
-95.29%
Share count reduction while CRVO shows 2.84% change. Joel Greenblatt would examine strategy.
-95.29%
Diluted share reduction while CRVO shows 2.84% change. Joel Greenblatt would examine strategy.